Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma

NCT01208896 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT01208896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01208896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2011
Completion date
September 28, 2017
Enrollment
32 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular, stem cell transplantation